Licensed Program Sample Clauses
POPULAR SAMPLE Copied 1 times
Licensed Program. Customer may terminate the license to any Licensed Program by providing written notice. Such notice may be provided at any time for perpetual licenses. Notices for term licenses must be provided thirty (30) days prior to the applicable renewal date. Absent such notification and unless otherwise stated in the applicable OST, the license shall automatically renew.
Licensed Program. Customer may terminate the license to any Licensed Program by providing DS with at least thirty (30) days prior written notice. Such notice may be provided at any time for perpetual licenses and thirty (30) days prior to the applicable renewal date for term based licenses. Absent such notification and unless otherwise stated in the applicable OST, the term based license shall automatically renew.
Licensed Program. Upon the effective date of termination or expiration of any license granted hereunder, (i) Customer shall immediately destroy or return all copies of all Releases of the terminated or expired Licensed Program and associated Documentation in their entirety and (ii) Customer shall duly certify the same in writing to No Magic.
Licensed Program. Customer may terminate the license to any Licensed Program by providing written notice. Such notice may be provided at any time for perpetual licenses.
Licensed Program. The computer program(s), consisting of a series of instructions or statements in machine readable, object code form only, licensed to Licensees by Licensor pursuant to License Agreements.
Licensed Program. Subject to the terms of this Agreement, effective upon the Clearance Date for the *** Licensed Program, MacroGenics hereby grants Gilead (a) an exclusive, royalty-bearing, non-transferable (except in accordance with Section 15.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics’ and its Affiliates’ interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs (other than Diagnostics) and Licensed Products from the *** Licensed Program in the Gilead Territory in the Field; and (b) an exclusive, royalty-bearing (to the extent provided in Section 8.5.3), non-transferable (except in accordance with Section 15.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics’ and its Affiliates’ interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from the *** Licensed Program in the Gilead Territory in the Field.
Licensed Program. The Licensed Program is the Program set forth on Exhibit A.
Licensed Program. (i) With respect to each Split Program or Co-Commercialized Program, following the end of the Discovery Term for such Licensed Program, except as otherwise expressly set forth in this Agreement or mutually agreed by the Parties:
(A) Agios shall be responsible for (1) if Celgene has requested Agios to conduct the first Phase I MAD Study pursuant to Section 3.6(b)(iii)(A)(2), conducting all Clinical Trials through Completion of Phase I MAD with respect to Licensed Compounds Developed under such Licensed Program, and (2) conducting other Development activities as may be contemplated under the Development Plan (but only such activities that Agios has consented to conduct); and
(B) Except as set forth in Section 3.10 with respect to any Split Program, Celgene shall be responsible for (1) conducting all Clinical Trials with respect to Licensed Compounds Developed under such Licensed Program following Completion of Phase I MAD, and (2) conducting other Development activities as may be contemplated under the Development Plan (but only such activities prior to Completion of Phase I MAD that Celgene has consented to conduct).
(ii) With respect to each (if any) Discovery Program directed to [**] that has not yet reached the DC Selection Stage as of the end of the Option Term, Agios shall be responsible for Development activities under the Discovery Plan for such Program until the earlier of (A) [**] years following the end of the Option Term and (B) IND Acceptance (or, if the DC Commitment is made, Completion of Phase I MAD) for a Development Candidate in such Program. If IND Acceptance is not achieved by [**] years following the end of the Option Term or, if IND Acceptance is achieved by such time but Celgene does not exercise the Celgene Program Option within the Celgene Option Exercise Period, except as provided in Section 8.9, all rights related to such Program(s) granted by Agios to Celgene hereunder shall terminate, and such Program(s) shall be deemed an Agios Reverted Program in accordance with Section 3.12.
(iii) With respect to each Buy-In Program, following the end of the Discovery Term for such Buy-In Program, except as otherwise expressly set forth in this Agreement or mutually agreed by the Parties, the Commercializing Party with respect to such Buy-In Program shall be responsible for all Development activities under such Buy-In Program.
(iv) With respect to each Picked Validated Program selected by Celgene, following the end of the Discovery Term for su...
Licensed Program. “Licensed Program” means the software made commercially available to CLIENT by FAI during the term of this Agreement as more particularly described in Exhibit B and any subsequent Purchase Order (each a “PO”), or other addendum attached and incorporated into this Agreement.
Licensed Program. This is a license agreement between You and Licensor with respect to Alepo RBS and\or Alepo Service Enabler, the accompanying Documentation and any fixes, releases, upgrades, new versions or enhancements that may subsequently be issued to You (the "Licensed Program").